search
Back to results

Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers

Primary Purpose

Foot Ulcer

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Collagen ORC Antimicrobial Matrix (CAM)
Sponsored by
Ethicon, Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Foot Ulcer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All Sexes

Inclusion Criteria: 18 years of age or older. Ambulatory (i.e. walking is the primary method of mobilization. Crutches, walker, walking frame or other ambulation aids are permitted). Diagnosed Type 2 diabetic (i.e. not juvenile onset). Have a DFU on the plantar surface of either foot. Have a DFU of >4 wks but <6 months duration. Willing and capable of cooperating to the extent and degree required by the study protocol Exclusion Criteria: Be < 1cm2 or >10cm2 in area, by planimetry. Demonstrate overt signs of infection. Be located on the dorsal, lateral, or posterior heel area of the foot (Change 2, Amendment 1). Have visible exposed bone or tendon. Have an adjacent thermal injury or wound of an etiology other than diabetes. Be within 5 cm of any other wound, regardless of etiology. Have received enzymatic debriding agents in the past 7 days. Have received topical antibiotic therapy in the past 7 days. Be less than 1 cm2 or exceed 10cm2 in area by planimetry, after debridement. Have exposed bone or tendon, after debridement The study subject MUST NOT: Have received previous treatment for the study ulcer by this Investigator. Have more than 3 full thickness ulcers, in total. Be pregnant or nursing an infant Have a concurrent illness or condition which may interfere with wound healing, such as carcinoma, vasculitis, immune system disorders or connective tissue disorder. Be a known alcohol or drug abuser. Have received systemic corticosteroids, immunosuppressive or chemotherapeutic agents in the past 30 days. Have received radiotherapy, which includes the lower extremity, at any time. Have a marked Charcot foot or claw foot deformity which would limit the ability of the subject to wear or be compliant with the wearing of the standardized off-loading device used in this study. Have received an investigational drug or device in the past 30 days. Have a known hypersensitivity to bovine collagen, oxidized regenerated cellulose (ORC) or silver. Be unwilling or unable to be fitted or compliant with the wearing of an ulcer off-loading device. Known to be non-compliant or unlikely to complete the study. Have ABPI < 0.7, OR, if ABPI >1.0 and toe pressure >0.6. Have serum Creatinine > 3 mg/dL25. have Hgb A1C>9%

Sites / Locations

  • Wound Care Center
  • Foot and Ankle Institute of South Florida
  • Penn North Centers for Advanced Wound Care

Outcomes

Primary Outcome Measures

Clinical effectiveness of CAM in DFU by comparing the reduction in wound area between 2 treatment groups.

Secondary Outcome Measures

Rate of wound closure
Ease of use and adverse events
Wound odor
Quality of life
Wound characteristics

Full Information

First Posted
October 6, 2005
Last Updated
October 12, 2006
Sponsor
Ethicon, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00235196
Brief Title
Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers
Official Title
A Study to Evaluate the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers
Study Type
Interventional

2. Study Status

Record Verification Date
October 2006
Overall Recruitment Status
Completed
Study Start Date
July 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2005 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Ethicon, Inc.

4. Oversight

5. Study Description

Brief Summary
This is a randomized (1:1), prospective, open label, multicenter, comparative study to be examine the effectiveness of Collagen-ORC Antimicrobial matrix, a new wound dressing, on diabetic foot ulcers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Foot Ulcer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
48 (false)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Collagen ORC Antimicrobial Matrix (CAM)
Primary Outcome Measure Information:
Title
Clinical effectiveness of CAM in DFU by comparing the reduction in wound area between 2 treatment groups.
Secondary Outcome Measure Information:
Title
Rate of wound closure
Title
Ease of use and adverse events
Title
Wound odor
Title
Quality of life
Title
Wound characteristics

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Eligibility Criteria
Inclusion Criteria: 18 years of age or older. Ambulatory (i.e. walking is the primary method of mobilization. Crutches, walker, walking frame or other ambulation aids are permitted). Diagnosed Type 2 diabetic (i.e. not juvenile onset). Have a DFU on the plantar surface of either foot. Have a DFU of >4 wks but <6 months duration. Willing and capable of cooperating to the extent and degree required by the study protocol Exclusion Criteria: Be < 1cm2 or >10cm2 in area, by planimetry. Demonstrate overt signs of infection. Be located on the dorsal, lateral, or posterior heel area of the foot (Change 2, Amendment 1). Have visible exposed bone or tendon. Have an adjacent thermal injury or wound of an etiology other than diabetes. Be within 5 cm of any other wound, regardless of etiology. Have received enzymatic debriding agents in the past 7 days. Have received topical antibiotic therapy in the past 7 days. Be less than 1 cm2 or exceed 10cm2 in area by planimetry, after debridement. Have exposed bone or tendon, after debridement The study subject MUST NOT: Have received previous treatment for the study ulcer by this Investigator. Have more than 3 full thickness ulcers, in total. Be pregnant or nursing an infant Have a concurrent illness or condition which may interfere with wound healing, such as carcinoma, vasculitis, immune system disorders or connective tissue disorder. Be a known alcohol or drug abuser. Have received systemic corticosteroids, immunosuppressive or chemotherapeutic agents in the past 30 days. Have received radiotherapy, which includes the lower extremity, at any time. Have a marked Charcot foot or claw foot deformity which would limit the ability of the subject to wear or be compliant with the wearing of the standardized off-loading device used in this study. Have received an investigational drug or device in the past 30 days. Have a known hypersensitivity to bovine collagen, oxidized regenerated cellulose (ORC) or silver. Be unwilling or unable to be fitted or compliant with the wearing of an ulcer off-loading device. Known to be non-compliant or unlikely to complete the study. Have ABPI < 0.7, OR, if ABPI >1.0 and toe pressure >0.6. Have serum Creatinine > 3 mg/dL25. have Hgb A1C>9%
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Hart, MD
Organizational Affiliation
Ethicon, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Wound Care Center
City
Ft. Lauderdale
State/Province
Florida
Country
United States
Facility Name
Foot and Ankle Institute of South Florida
City
South Miami
State/Province
Florida
Country
United States
Facility Name
Penn North Centers for Advanced Wound Care
City
Warren
State/Province
Pennsylvania
ZIP/Postal Code
16365
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers

We'll reach out to this number within 24 hrs